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In this study, endothelial cell-mediated clot retraction
was supported by fibrin generated from several purified
fractions of plasma fibrinogen, purified proteolytic frag-
ments of plasma fibrinogen, recombinant normal fibrin-
ogen, and recombinant variant fibrinogen. These results
were surprising because some of these fibrinogens lack
domains that are known binding sites for the integrin
receptors that support clot retraction. Specifically, fi-
brinogens lacking Aa-chain RGD residues at 572–574 or
lacking the g-chain residues AGDV 408–411 supported
endothelial cell-mediated clot retraction as well as in-
tact fibrinogen. Thus, clot retraction mediated by endo-
thelial cells is not dependent on either of these sites. A
variety of monoclonal antibodies against the integrin
avb3 partially inhibited the endothelial cell-mediated
retraction of clots formed from plasma fibrinogen. As
expected, an antibody to the platelet integrin aIIbb3 did
not inhibit endothelial cell-mediated clot retraction.
These results indicate that this retraction is mediated at
least in part by avb3. These results support the conclu-
sion that (a) neither of the two fibrinogen cell binding
sites described above is required to support clot retrac-
tion or that (b) either site alone or in conjunction with
other fibrin(ogen) region(s) can support clot retraction.
Thus, endothelial cell-mediated clot retraction appears
to be dependent on fibrinogen cell binding sites other
than those required to support adhesion of resting
platelets to immobilized fibrinogen and platelet
aggregation.
This study was undertaken to evaluate the role in clot re-
traction mediated by endothelial cells of presumptive endothe-
lial cell and platelet binding sites on fibrinogen. Platelets,
fibroblasts, melanoma cells, and endothelial cells are known to
support clot retraction (1–4). However, it is not known whether
clot retraction mediated by endothelial cells is dependent on
either the presumptive endothelial cell fibrinogen Aa-chain
binding site, the 572–574 RGD residues (5), or the fibrinogen
gA-chain carboxyl-terminal AGDV sequence as is resting plate-
let adhesion to immobilized fibrinogen (6, 7) and platelet ag-
gregation (8, 9).
Clot retraction is dependent on fibrin binding to activated
aIIbb3 in platelets (10, 11) or to the homologous integrin avb3
(12, 13) in nucleated cells (3, 4). Katagiri et al. (3) used mono-
clonal antibodies and immunoelectron microscopy to show that
clot retraction mediated by melanoma cells is dependent on
fibrin binding to unstimulated avb3. In their study, clot retrac-
tion mediated by melanoma cells was blocked by RGD-contain-
ing peptides and anti-b3 as well as anti-avb3 mAbs
1 but not by
an aIIbb3-specific inhibitor. The conclusion that avb3 can sup-
port clot retraction mediated by nucleated cells was confirmed
by Chen et al. (4). Alemany et al. (14) provided evidence that a
fibrinogen gA-chain binding region of the platelet integrin
aIIbb3 is on its b3 subunit and that ligand binding to this site is
independent of platelet activation. Their results support the
possibility that the avb3 integrin of endothelial cells, like the
homologous aIIbb3 on platelets, may be able to bind fibrinogen
via the gA-chain carboxyl termini and that this hypothetical
binding may play a role in endothelial-mediated clot retraction.
Fibrinogen platelet binding sites have been identified using
a variety of experimental systems. Farrell et al. (8) used recom-
binant forms of fibrinogen to show that platelet aggregation
appears to be dependent on residues within the sequence 408–
411 of the fibrinogen gA-chain. This was shown more directly
by Rooney et al. (9). These observations confirmed and ex-
tended earlier results obtained using aggregated genetically
modified g-chains (15). Under static conditions, the adhesion of
both resting and stimulated platelets to immobilized fibrinogen
appears to be dependent on the fibrinogen gA-chain carboxyl-
terminal platelet binding sites (6, 7, 16). The activation-inde-
pendent adhesion of platelets to fibrinogen also appears to be
dependent on the fibrinogen gA-chain carboxyl-terminal plate-
let binding sites under flow conditions (17). Rooney et al. (9),
using a recombinant form of fibrinogen (without the gA-chain
terminal sequence AGDV on either gA-chain), tested gA-chain
involvement in platelet aggregation and clot retraction. The
recombinant fibrinogen did not support platelet aggregation in
response to ADP but did support clot retraction. Therefore, the
ligand sites on fibrinogen that support platelet aggregation
may be different than the sites on fibrin that support clot
retraction. These latter studies did not exclude the possibility
that normal fibrinogen secreted from the platelet a granules
may have provided functional fibrinogen gA-chains to support
the clot retraction. However, a recent study by Holmback et al.
(18) confirms the conclusion of Rooney et al. (9) by demonstrat-
ing that mice which have only fibrinogen lacking the QAGDV
sequence of both g-chains can support clot retraction even
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though the altered fibrinogen cannot support platelet aggrega-
tion. These results raise the interesting possibility that non-g-
chain platelet binding sites on fibrinogen can support platelet-
mediated clot retraction (9, 18).
Others have reported the blocking of clot retraction by certain
RGD-containing peptides (presumably by binding to the recep-
tors that mediate retraction). Unfortunately this inhibition did
not identify the receptor binding site(s) on the ligand (10, 11).
Likewise, the role of the gA-chain carboxyl-terminal platelet
binding regions is not clear. Despite the fact that the gA-chain
carboxyl-terminal peptide mimetics LGGAKQAGDV (L10) and
HHLGGAKQAGDV (H12) have been shown to inhibit platelet-
mediated clot retraction (10), the dependence of clot retraction on
the corresponding platelet binding sites on fibrinogen has not
been shown. In fact, as described above, recent evidence demon-
strates that clot retraction mediated by human and mouse plate-
lets is not dependent on the AGDV sequence of the fibrinogen
gA-chain (9, 18). Thus, care must be taken in interpreting the
results of peptide inhibition studies (19).
In the experiments described here, human umbilical vein
endothelial cells (HUVECs) were tested in clot retraction as-
says because, unlike platelets, they do not secrete fibrinogen in
response to treatment with thrombin. Thus, various forms of
exogenous fibrinogen in conjunction with HUVECs would be
useful to try to identify the cell binding site(s) on fibrinogen
that is required to support clot retraction. Peak 1 fibrinogen
(gAgA), fibrinogen fraction I-9 (a fibrinogen fragment that
lacks about 100 carboxyl-terminal residues from each Aa-chain
including the 572–574 RGD sequence and that is bivalent with
respect to the gA-chain binding sites (20)), peak 2 fibrinogen
fraction I-9 (a fragment of peak 2 fibrinogen that has one
platelet reactive gA-chain and one nonplatelet reactive g9-
chain and the same Aa-chain composition as fibrinogen frac-
tion I-9), recombinant normal human fibrinogen (9), recombi-
nant fibrinogen g407, which lacks residues 408–411 in both
gA-chains (9), and the mAb 4A5 (a mAb specific for the car-
boxyl-terminal region of the gA-chain) (21) were used to eval-
uate the role of presumptive fibrinogen cell binding sites in clot
retraction mediated by HUVECs.
EXPERIMENTAL PROCEDURES
Cell Culture—HUVECs and endothelial cell growth medium (con-
taining 10 ng/ml human recombinant epidermal growth factor, 1 mg/ml
hydrocortisone, 50 mg/ml gentamicin, 50 ng/ml amphotericin B, 3 mg/ml
bovine brain extract, 2% fetal bovine serum) were purchased from
Clonetics Corp. (San Diego, CA). The cells were grown to 80–95%
confluence, and then a 0.025% trypsin, 0.01% EDTA solution (Clonetics)
was used to release the cells from the surface of the flask, after which
trypsin neutralization solution (Clonetics) was added. The cell suspen-
sion was centrifuged at 220 3 g for 5 min, the supernatant liquid was
decanted, and the cells were suspended in fresh endothelial cell growth
medium. The suspended cells were allowed to recover from trypsiniza-
tion by incubation for 30 min at 37 °C before use in the clot retraction
assay.
Clot Retraction—The clot retraction assay was a modification of
published methods (3, 4, 10). The cell suspension was centrifuged, the
liquid was decanted, and the cells were washed three times with a
Tyrodes Hepes solution (150 mM NaCl, 2.5 mM KCl, 2.0 mM MgCl2, 5.0
mM Hepes, pH adjusted to 7.35) containing 1 mg/ml glucose and 3.5%
bovine serum albumin. The washed cells were added to the incubation
solution (wash solution containing 2 mM CaCl, 3 mg/ml aprotinin, and
250 mg/ml fibrinogen or fragment) and allowed to incubate for 5 min at
37 °C. Cell numbers were estimated using a hemocytometer. ;2 3 105
cells were suspended in 0.5 ml of clotting medium (250 mg/ml fibrinogen
or fragment in Tyrodes Hepes solution containing glucose, bovine se-
rum albumin, CaCl2, and aprotinin) in a sylanized (using trimethylsy-
lyl) aggregometer cuvette. mAbs that bind integrins were added to cells
in incubation buffer before addition to clotting medium. mAbs that bind
fibrinogens or their fragments were added to the clotting medium before
the addition of the cells. Thrombin (Sigma) (1 unit/ml) was added to
inititate fibrin formation. The retracting clot was photographed at
several time intervals, and the photos were traced on a back-lit digitiz-
ing pad (Ortho-Graphics, Inc.) providing automated data entry into a
computer. The longitudinal cross-sectional area not occupied by the clot
was calculated and expressed as a percentage of the total area. The
results are reported as percent clot retraction where 0% is no retraction
and 100% would be complete retraction, which is undefined. Each clot
retraction experiment was repeated at least once. Some experiments
were repeated only once due to the large amount of antibodies and
recombinant fibrinogen required. Although data are presented as quan-
titative, these studies are not meant to be a stringent quantitative
analysis; however, the experiments provide unequivocal data as to the
support or inhibition of HUVEC-mediated clot retraction by the forms of
fibrinogen, antibodies, and peptides used in the experiments described
above.
Antibodies—mAbs used were LM609 (50 mg/ml), which binds to the
avb3 receptor (22); CLB-706 (50 mg/ml), which binds to av (LM609 and
CLB-706 were from Chemicon International, Inc.); 7E3 (50 mg/ml),
which binds to aIIbb3 (23) and avb3 (24) (courtesy of Dr. Barry Coller);
A2A9 (50 mg/ml), which binds to aIIbb3 (25) (courtesy of Dr. J.S. Ben-
nett); AP3 (100 mg/ml), which binds the b3 subunit (26) (courtesy of Dr.
Peter Newman); 4A5 (21) 50 mg/ml (courtesy of Dr. Gary Matsueda),
which binds the fibrinogen gA-chain carboxyl terminus and prevents
platelet adhesion; and JB1a (1:100 dilution from ascites fluid), an
anti-b1 antibody (27). Mouse IgG (mIgG) (Sigma) (50 mg/ml) was used as
control IgG.
Fibrinogens—The following fibrinogens were used in this study to
identify the binding sites utilized by endothelial cells to support clot
retraction: peak 1 fibrinogen (gAgA) (6), peak 1 fibrinogen fraction I-9
(20), peak 2 fibrinogen fraction I-9 (6), and fibrinogen 325, which lacks
the first 42 amino acids (amino terminus) of the Bb-chains (28, 29). The
fibrinogens used and the important binding sites present or absent on
each form are listed in Table I. Peak 1 (gAgA) and peak 2 (gAg9)
fibrinogens were prepared as described by Mosesson and Finlayson (30)
from fraction I-2 fibrinogen (31) containing .80% intact Aa-chains (20)
or from fraction I-9 fibrinogen (20). Fraction I-9 fibrinogen is devoid of
intact Aa-chains and contains instead Aa-chain derivatives of the size
of Bb-chains (54 kDa) or smaller (20) that lack carboxyl-terminal seg-
ments. Its composition was verified by SDS-polyacrylamide gel electro-
phoresis. Chromatographic separation into peak 1 and peak 2 subfrac-
tions was verified by DEAE-cellulose ion exchange chromatography
using the gradient elution system described by Siebenlist et al. (32).
Fibrinogen 325 (des-Bb1–42 fibrinogen) that lacks the first 42 amino
acids of Bb-chains (33) was produced from fraction I-2 fibrinogen as
described by Pandya et al. (28) and Pandya and Budzynski (29). Its
structure was verified by SDS-polyacrylamide gel electrophoresis.
Normal recombinant fibrinogen and recombinant fibrinogen g407
(which lacks residues 408–411 on both gA-chains) were synthesized by
transfected Chinese hamster ovary cells, and purification was moni-
tored as described (9). Briefly, samples were run on SDS-polyacryl-
amide gel electrophoresis under reduced conditions according to the
method of Laemmli (34) and appeared as three bands corresponding to
the Aa-, Bb-, and g-chains. Western blot analysis was performed as
described (35) using 4A5. Normal recombinant and plasma fibrinogen
developed bands corresponding to the g-chain; however, the g-chain
from g407 fibrinogen was undetectable, consistent with previous results
(9).
Peptides—Peptide inhibitors of fibrinogen binding to platelets were
tested as inhibitors of endothelial cell-mediated clot retraction. The
peptide LGGAKQAGDV, a gA-chain carboxyl-terminal fibrinogen pep-
tide mimetic, GRGDSP, and a control scrambled version of GRGDSP,
PGRSGD, were tested in the clot retraction assay at different concen-
trations. Quantity and sequences were verified by St. Jude Children’s
Research Hospital Biotechnology Center laboratories. The methods
used for the synthesis, purification, and characterization of these pep-
tides have been described (19).
RESULTS
Endothelial cells retracted clots formed from thrombin-
treated peak 1 fibrinogen gAgA, peak 1 fibrinogen fraction I-9,
and peak 2 fibrinogen fraction I-9 (Fig. 1). The rates of clot
retraction mediated by the HUVECs were approximately the
same for all three types of fibrinogen used in these experiments
(Fig. 2). The ability of peak 1 fibrinogen fraction I-9 to support
clot retraction mediated by the endothelial cells means that the
Aa-chain RGD (572–574) sequence was not required for retrac-
tion. Furthermore, the fact that clot retraction was also sup-
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ported by peak 2 fibrinogen fraction I-9 demonstrates that if
the carboxyl terminus of the gA-chain is required to support
clot retraction, a single g-chain is sufficient.
The mAb 4A5 was used to determine if endothelial cell-
mediated clot retraction is dependent on the carboxyl terminus
of the fibrinogen gA-chain. This mAb antibody was used be-
cause it binds to the carboxyl terminus of the fibrinogen gA-
chain (19) and thereby inhibits cross-linking of fibrinogen by
Factor XIIIa (19) and the adhesion of platelets to immobilized
fibrinogen (6). As shown in Fig. 3, the mAb 4A5 inhibited the
retraction of clots formed from both peak 1 fibrinogen and
fibrinogen fraction I-9 compared with mIgG controls. This in-
hibition of endothelial cell-mediated clot retraction by the mAb
4A5 indicated either a requirement for the gA-chain carboxyl
terminus or an indirect inhibitory effect on clot retraction by
the antibody. To distinguish between these alternatives, re-
combinant fibrinogen containing normal Aa- and Bb-chains,
but lacking residues gA408–411 (9) was used in the clot re-
traction assay. Recombinant normal fibrinogen was used as a
control. The recombinant normal fibrinogen supported the ad-
hesion of normal and resting platelets (data not shown) and clot
retraction in HUVECs (Fig. 1). Likewise, recombinant fibrino-
gen g407, though it did not support the adhesion of resting
platelets (data not shown), supported clot retraction mediated
by HUVECs without any apparent impairment of function
(Figs. 1 and 4).
Fibrinogen 325, which lacks the first 42 amino acid residues
of the Bb-chains was also used in the clot retraction assay. It
has been shown that fibrin prepared from fibrinogen molecules
lacking residues 1–42 of the Bb-chains failed to support endo-
thelial cell spreading (36, 37). Fibrinogen 325 in this study
supported HUVEC clot retraction (data not shown).
Two peptides that inhibit platelet-mediated clot retraction
were tested in the HUVEC system (10). Although gA-chain
carboxyl-terminal mimetic peptide L10 (LGGAKQAGDV) in-
hibited platelet-mediated clot retraction (data not shown), it
did not inhibit retraction in the HUVEC system at the concen-
FIG. 3. Inhibition of clot retraction by mAb 4A5. Bars represent
the percentage of control retraction (fibrinogen/mIgG) for fibrinogen
4A5 and fibrinogen fraction I-9 4A5 after 7.5 h. gAgAFg/mIgG, peak 1
fibrinogen; Fr I-9, fibrinogen peak 1 fraction I-9, which lacks the Aa-
chain 572–574 RGD sequences. mAb 4A5 binds the carboxyl-terminal of
the fibrinogen gA-chain. All fibrinogens were at 250 mg/ml concentra-
tion, thrombin was at 1 unit/ml, and 4A5 was 50 mg/ml. Data are
presented as the mean 6 standard error. Fg, fibrinogen; Fr, fraction.
n 5 3.
FIG. 1. Clot retraction for human umbilical vein endothelial cells. Fg gAgA, peak 1 fibrinogen; Fr I-9, fibrinogen peak 1 fraction I-9, which
lacks the Aa-chain 572–574 RGD sequences; Fg gAg9, fibrinogen peak 2 fraction I-9, which lacks one gA-chain carboxyl-terminal platelet binding
region as well as the same Aa-chain sequences as fraction I-9; rFg, recombinant normal fibrinogen; rFg 407, recombinant fibrinogen missing the
gA-chain carboxyl-terminal 408–411 AGDV sequences. All fibrinogens were at 250 mg/ml concentration, and thrombin concentration was 1
unit/ml.
FIG. 2. Time course of endothelial cell-mediated clot retrac-
tion. Fg gAgA, peak 1 fibrinogen; Fr I-9, fibrinogen peak 1 fraction I-9,
which lacks the Aa-chain 572–574 RGD sequences; Fg I-9 gAg9, fibrin-
ogen peak 2 fraction I-9, which lacks one gA-chain carboxyl-terminal
platelet binding region as well as the same Aa-chain sequences as
fraction I-9. All fibrinogens were at 250 mg/ml concentration, and
thrombin concentration was 1 unit/ml. n 5 1.
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trations up to 6 mM (Fig. 5). In contrast, the RGD peptide
GRGDSP, but not a scrambled control peptide (PGRSGD), in-
hibited clot retraction mediated by platelets (10) (data not
shown) and endothelial cells (Fig. 5).
Anti-integrin mAbs also provided useful information con-
cerning the details of endothelial cell-mediated clot retraction.
First, the avb3-specific mAb LM609 partially inhibited clot
retraction (Fig. 6A). The av-specific mAb CLB-706 also inhib-
ited clot retraction (Fig. 6A). These results confirm observa-
tions made by others (3, 4) indicating a role for the avb3 inte-
grin in clot retraction mediated by a variety of nucleated cells.
Similarly, the mAb 7E3, but not A2A9, inhibited clot retraction
in HUVECs (Fig. 6B). In contrast, both of those mAbs inhibited
platelet-mediated clot retraction, presumably reflecting a role
for aIIbb3 in the process (Fig. 6B). These data demonstrate that
clot retraction mediated by HUVECs is avb3-dependent since
LM609, CLB-706, and 7E3 but not A2A9 or JB1a (which blocks
the function of b1 integrin subunits) can inhibit avb3-depend-
ent functions. Finally, the AP3 mAb, which binds to the b3
integrin subunit and can inhibit platelet-mediated clot retrac-
tion (10, 28), also partially inhibited (at a concentration of 100
mg/ml) clot retraction in the HUVEC system (Fig. 6A). The
aIIbb3-specific mAb Tab, which also inhibits platelet-mediated
clot retraction (10), did not inhibit endothelial cell-mediated
clot retraction (50 mg/ml) compared with a mouse IgG control
(data not shown).
DISCUSSION
Studies by Cheresh et al. (5) and others (16) provide evidence
implicating the fibrinogen Aa-chain RGD 572–574 sequence as
a putative endothelial cell binding site recognized by avb3 (22).
These studies also demonstrated that the fibrinogen Aa-chain
95–97 RGD residues do not play a significant role in HUVEC
adhesion to fibrinogen (5, 16). mAb data indicated that endo-
thelial cell adhesion to this region of immobilized fibrinogen
FIG. 4. Endothelial cell-mediated clot retraction with recom-
binant fibrinogen and recombinant g407 fibrinogen that lacks
residues g408–411. gAgA Fg, peak 1 fibrinogen (n 5 3); Fr I-9,
fibrinogen peak 1 fraction I-9 (n 5 3), which lacks the Aa-chain 572–574
RGD sequences; rFg, recombinant normal fibrinogen (n 5 2); rFg407,
recombinant fibrinogen missing the gA-chain carboxyl-terminal 408–
411 AGDV sequences (n 5 2). All fibrinogens were at 250 mg/ml con-
centration, and thrombin was 1 unit/ml. Data represent retraction 5 h
after the addition of thrombin. The data is presented as the mean 6
standard deviation.
FIG. 5. Peptide dose response of endothelial cell-mediated clot
retraction. L10, LGGAKQAGDV mimetic of the fibrinogen gA-chain
platelet binding region. GRGDSP contains the RGD sequence that
mimics the fibrinogen 572–574 Aa-chain binding region. PGRSGD is a
scrambled control version of GRGDSP. Inhibition after 4 h is shown for
endothelial cells. '170,000 cells, 250 mg/ml fibrinogen, and 1 unit/ml
thrombin per tube were used.
FIG. 6. Antibody inhibition of platelet and endothelial cell-
mediated clot retraction. A, LM609 (50 mg/ml) binds to the avb3
receptor, CLB-706 (50 mg/ml) binds to av, AP3 (100 mg/ml) binds the b3
subunit, and JB1a (1:10 dilution from ascites fluid) binds the b1 subunit
(n 5 1). B, 7E3 (100 mg/ml) binds both avb3 and aIIbb3 integrins, and
A2A9 (50 mg/ml) is aIIbb3-specific. mIgG, a mouse control IgG, concen-
tration is 50 mg/ml. Data represent retraction 4 h after the addition of
1 unit/ml thrombin. The data are presented as the mean 6 standard
deviation. (n 5 3)
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was mediated by the integrin avb3 (5, 22). Consequently, the
possibility was tested that the fibrinogen Aa-chain 572–574
sequence is required to support avb3-mediated clot retraction
by HUVECs. This possibility was tested by using fibrinogen
fragment fraction I-9 in an endothelial cell-supported clot re-
traction assay. Surprisingly, the fibrinogen fraction I-9 (Table
I) supported apparently normal clot retraction. These results
mean that the Aa-chain RGD (572–574) sequence is not re-
quired for clot retraction mediated by HUVECs.
The finding that HUVECs-mediated clot retraction is not
dependent on the fibrinogen Aa-chain RGD 572–574 sequence
resulted in the evaluation of the role of the fibrinogen gA-chain
carboxyl-terminal sequences in the endothelial cell clot retrac-
tion system. Four approaches were used for this aspect of the
study. Proteolytic fragments of fibrinogen, an anti-fibrinogen
mAb, recombinant fibrinogens, and peptides were used in these
studies. Peak 2 fibrinogen fraction I-9 (Table I) was found to
support HUVEC-mediated clot retraction normally (Fig. 1),
demonstrating that if a fibrinogen g-chain carboxyl terminus is
required, a single functional gA-chain carboxyl terminus is
sufficient even in the absence of the Aa-chain 572–574 RGD
sequences. The mAb 4A5 results reflected either a requirement
for the gA-chain carboxyl-terminal platelet binding site or in-
direct inhibitory effects caused by 4A5 (Fig. 3). Use of recom-
binant human fibrinogen, which does not support platelet ag-
gregation (9) or the adhesion of resting platelets (data not
shown), supported normal clot retraction in the endothelial cell
clot retraction system (Fig. 4). These results demonstrate that
the inhibition of clot retraction by mAb 4A5 apparently re-
sulted from indirect effects (steric hindrance or the induction of
an incompatible conformational change of the fibrinogen), since
clot retraction was not dependent on the presence of the AGDV
sequence of the fibrinogen gA-chain. The gA-chain carboxyl-
terminal mimetic peptide L10 has been shown to inhibit plate-
let-supported clot retraction (10) but did not inhibit clot retrac-
tion at concentrations up to 6 mM mediated by endothelial cells
in our assays (Fig. 5). The data from the proteolytic fragments
of fibrinogen, an anti-fibrinogen mAb, recombinant fibrino-
gens, and peptides demonstrate that HUVEC-mediated clot
retraction is not dependent on the 408–411 AGDV sequence of
the fibrinogen gA-chain. Thus, the fibrinogen cell binding sites
required to support endothelial cell-mediated clot retraction
are different than those required to support platelet aggrega-
tion (8, 9) and adhesion (6, 7, 16, 17).
The amino-terminal region of the fibrinogen Bb-chain is a
presumptive endothelial cell interaction site. Since this region
of the Bb-chain appears to affect the interaction of HUVECs
with fibrin, a protease-treated form of fibrinogen that lacks the
first 42 amino acid residues of the Bb-chains (fibrinogen 325)
(28, 29) was tested and shown to support clot retraction (data
not shown). Even though this region has been shown to interact
with HUVECs, it is not necessary to support HUVECs clot
retraction. The amino-terminal 42 residues of the Bb-chains
are therefore not required to support clot retraction mediated
by HUVECs.
The results of this study reveal that HUVECs can mediate
clot retraction in a manner that is not dependent on the Aa-
chain 572–574 RGD sequences, the 408–411 AGDV sequence
of the gA-chain carboxyl-terminal platelet binding sites, or
residues 1–42 of the fibrinogen Bb-chains. In summary, the
data mean that (a) either of these fibrinogen cell binding sites
may be sufficient to support clot retraction mediated by HU-
VECs or that (b) another region(s) of fibrinogen alone or in
conjunction with either of the above mentioned fibrinogen
platelet or nucleated cell binding sites can be utilized by endo-
thelial cells to support clot retraction.
The data presented here for HUVECs agree with those re-
ported by others for the role of the fibrinogen gA-chain in clot
retraction mediated by platelets (9, 18). Rooney et al. (9) report
that the aIIbb3 binding sites on fibrinogen that mediate platelet
aggregation appear to differ from the aIIbb3 binding site(s) on
fibrin that are used during clot retraction (9). Their conclusion
that the gA-chain 408–411 AGDV sequence is not required for
clot retraction was supported by the results of Holmback et al.
(18) obtained using homozygous mutant mice. The results pre-
sented here extend the observation that the AGDV sequence is
not required to support clot retraction to a new system, the
endothelial cell clot retraction system. Additionally, these re-
sults demonstrate that clot retraction in this system is not
dependent on either the Aa-chain 572–574 RGD sequence or
the Bb-chain 1–42 residues.
A role for the avb3 integrin in endothelial cell-mediated clot
retraction is supported by the facts that the avb3-specific mAb
LM609, the av-specific mAb CLB-706, and the mAb 7E3, which
blocks both avb3 and aIIbb3, inhibited endothelial cell-mediated
clot retraction, whereas the aIIbb3-specific A2A9 and the an-
ti-b1 function blocking mAb, JB1a, did not inhibit clot retrac-
tion in this system. The fact that the mAb AP3 partially inhib-
ited clot retraction may indicate a role for residues within the
b3 348–426 sequence, which encompass the AP3 binding site,
in clot retraction mediated by endothelial cells as well as plate-
lets, since AP3 has also been shown to inhibit platelet-medi-
ated clot retraction (10, 38). Alternatively, the inhibitory effect
of AP3 may be indirect.
Finally, the observations that sites other than the gA-chain
408–411 AGDV sequences and the Aa-chain 572–574 se-
quences appear to be required for both platelet (fibrinogen
fraction I-9 supports platelet-mediated clot retraction, data not
shown) and HUVEC-mediated clot retraction may mean that
receptor sites other than those used for platelet aggregation
and platelet and endothelial cell adhesion are used to bind
fibrin during clot retraction mediated by either platelets or
HUVECs.
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